CGP is an assay that utilizes next-generation sequencing (NGS) to assess multiple established biomarkers present within a solid tumor. CGP detects at a genomic resolution that allows for the identification of variant classes such as SNVs, indels, CNVs, fusions, splice variants, as well as cancer genomic signatures such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI).

The breadth of this single assay allows for a robust understanding of a tumor profile, alleviating the need to use multiple tumor-specific panels or different modalities of testing. The panel is also compatible with Twist’s enzymatic fragmentation library preparation and target enrichment reagents. Twist’s CGP panel can also be supplemented with custom targets to include additional biomarkers.